spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Synpromics expands facilities to meet demand for revolutionary gene control technology

Synpromics

It is the first company to move into the new custom-built centre based at the University of Edinburgh’s Easter Bush Campus

Edinburgh, UK, 11th September 2017 - Synpromics Ltd, the leader in gene control and synthetic promoter development, today moves to new world-class facilities at the Roslin Innovation Centre. Synpromics is expanding to meet increasing global demand for its cutting-edge gene control technology, and is the first company to move into the new custom-built centre based at the University of Edinburgh’s Easter Bush Campus.

David Venables, CEO of Synpromics, explained, “Our move to Roslin is the result of two incredibly successful years for the company. In 2017 alone, we’ve signed gene therapy deals with a large, orphan disease pharma company and most recently with a US biotech specialising in gene editing and developing rare disease gene therapies. We’ve also signed bioprocessing deals with a top-10 pharma company and a global CDMO. Currently, the company has over ten active commercial gene therapy programmes and five bioprocessing programmes underway.

Over that time Synpromics’ team has grown by over 100% and is one of our greatest assets. We look forward to working in our new high tech facilities as we continue to build the company for the future.”

CSO and founder of Synpromics, Dr Michael Roberts, added that “the company’s recent successes have been greatly accelerated by our revolutionary PromPT technology. PromPT is our unique bioinformatics engine, the culmination of over 10 years’ work, to enable data-driven synthetic promoter design. It has been hugely important in helping us build an extensive IP portfolio, for both our partners and ourselves, and is of substantial commercial value. We are particularly pleased with the suite of tightly regulated inducible promoters that we have created using our platform, and the excitement they generated at The Bioprocessing Summit in Boston this year.”

Dr John Brown, Chairman of Synpromics, also announced today that the company is expanding its Board. “We’re delighted to welcome Dr Alan Lamont to Synpromics as a non-executive director. Alan has extensive experience that will be extremely valuable to us as we grow. He’s held senior corporate and business development roles with leading UK and US companies including Acambis, AstraZeneca, Eli Lilly and Mundipharma International.”

The Roslin Innovation Centre is a multi-purpose building offering 41,000sq ft of flexible laboratory and office space. Synpromics will occupy both labs and open plan offices at the new facility. John Mackenzie, CEO of Roslin Innovation Centre, said, “Synpromics, as one of the UK’s most innovative companies working in gene medicine, is an ideal fit for our profile. Synpromics’ innovation has been attracting attention within the life sciences community and we look forward to providing an environment conducive for the business to realise its long-term growth ambition.”

About Synpromics
Synpromics is the leader in gene control, improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data-driven design. The Company has developed PromPT, its multi-dimensional bioinformatics database that enables product-specific promoter design and selection empowering the next generation of cell and gene based medicines and bioprocessing applications. The company operates in a diverse range of fields, including broad applications in cell and gene based medicine, biologics manufacturing and viral vector bioprocessing. Current partners include Adverum, uniQure, AGTC, GE Healthcare and Sartorius-Stedim Cellca as well as numerous undisclosed partners in the pharmaceutical sector.

About synthetic promoters
Naturally occurring promoters have evolved for biological functions but have limitations when utilised in industrial or therapeutic applications. Synthetic promoters with DNA sequences not found in nature are designed to better regulate gene activity and precisely control protein production. Synpromics creates highly specific promoters designed to drive gene expression at the desired level and specificity in any cell type, tissue or environmental condition. Each synthetic promoter represents a novel invention and thus can be patented. For more information visit www.synpromics.com

Corporate Contact
Dr David Venables
Synpromics Ltd
+44 (0)7825 323439
david.venables@synpromics.com

Media Contact
Deborah Cockerill/ Emma Pickup
Sciad Communications Ltd
+44 (0)20 7470 8801
synpromics@sciad.com
phone +44 (0) 131 651 9662
email info@synpromics.com
web www.synpromics.com
email Roslin Innovation Centre, Easter Bush Campus, Midlothian, EH25 9RG
 
Print this page
Send to a friend
   
spacer
News and Press Releases

TP3 Global receives Royal recognition by winning the Queen’s Awards for Enterprise 2018

Birmingham, UK, 23 April 2018 – TP3 Global, a leading global innovator and provider of thermal protection for temperature sensitive cargo, is pleased to announce it has been awarded the 2018 Queen’s Awards for Enterprise in the International Trade category for its globally-recognised Silverskin™ brand.
More info >>


White Papers

pAVEway™ expression system for the efficient expression of therapeutic proteins

Fujifilm Diosynth Biotechnologies

One of the major bottlenecks in the production of biopharmaceuticals is the efficient expression of therapeutic proteins in microbial or mammalian cells. The Escherichia coli pAVEway™ expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimising many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).
More info >>

Industry Events

HPLC 2018

29 July - 2 August 2018, Washington Marriott Wardman Park, Washington, DC, USA

Are you interested in mass spectrometry, chromatography, or electrophoresis? Are you solving complex analytical problems? Are you looking for a conference with strong scientific content, a robust program, presentations by world renowned experts, lectures by young scientists, courses offering great training opportunities, tutorials, panel discussions, vendor technical workshops, best poster competition, and a major exposition showcasing new product launches and innovative products? Mark your calendar to attend HPLC 2018 Washington, DC, the largest, most recognized international conference in the world devoted to advances in separation technologies!
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement